Preclinical pharmacological profile of nomegestrol acetate, a synthetic 19-nor-progesterone derivative

Autor: van Diepen Harry A

Publikováno v: Reproductive Biology and Endocrinology, Vol 10, Iss 1, p 85 (2012)

Abstract Background Nomegestrol acetate (NOMAC), a synthetic progestogen derived from 19-nor-progesterone, recently completed clinical trials for use with 17beta-estradiol in a new monophasic combined oral contraceptive. In this review, published as

Externí odkaz: https://doaj.org/article/cbb1a45ef38343328442ada00fedb7de

A small-molecule fusion inhibitor of influenza virus is orally active in mice.

Autor: van Dongen MJP; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands. mvandon@its.jnj.com wilson@scripps.edu.; Discovery Sciences, Janssen Research & Development, Turnhoutseweg 30, Beerse, Belgium., Kadam RU; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA., Juraszek J; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands., Lawson E; Discovery Sciences, Janssen Research & Development, 1400 McKean Rd., Spring House, PA, USA., Brandenburg B; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands.; Janssen Infectious Diseases and Vaccines, Janssen Research & Development, Archimedesweg 4-6, Leiden, Netherlands., Schmitz F; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands., Schepens WBG; Discovery Sciences, Janssen Research & Development, Turnhoutseweg 30, Beerse, Belgium., Stoops B; Discovery Sciences, Janssen Research & Development, Turnhoutseweg 30, Beerse, Belgium., van Diepen HA; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands., Jongeneelen M; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands.; Janssen Infectious Diseases and Vaccines, Janssen Research & Development, Archimedesweg 4-6, Leiden, Netherlands., Tang C; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands.; Janssen Infectious Diseases and Vaccines, Janssen Research & Development, Archimedesweg 4-6, Leiden, Netherlands., Vermond J; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands., van Eijgen-Obregoso Real A; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands., Blokland S; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands.; Janssen Infectious Diseases and Vaccines, Janssen Research & Development, Archimedesweg 4-6, Leiden, Netherlands., Garg D; Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA., Yu W; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA., Goutier W; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands., Lanckacker E; Janssen Infectious Diseases and Vaccines, Janssen Research & Discovery, Turnhoutseweg 30, Beerse, Belgium., Klap JM; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands., Peeters DCG; Discovery Sciences, Janssen Research & Development, Turnhoutseweg 30, Beerse, Belgium., Wu J; Janssen Infectious Diseases and Vaccines, Janssen Research & Discovery, Turnhoutseweg 30, Beerse, Belgium., Buyck C; Discovery Sciences, Janssen Research & Development, Turnhoutseweg 30, Beerse, Belgium., Jonckers THM; Janssen Infectious Diseases and Vaccines, Janssen Research & Discovery, Turnhoutseweg 30, Beerse, Belgium., Roymans D; Janssen Infectious Diseases and Vaccines, Janssen Research & Discovery, Turnhoutseweg 30, Beerse, Belgium., Roevens P; Discovery Sciences, Janssen Research & Development, Turnhoutseweg 30, Beerse, Belgium., Vogels R; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands.; Janssen Infectious Diseases and Vaccines, Janssen Research & Development, Archimedesweg 4-6, Leiden, Netherlands., Koudstaal W; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands., Friesen RHE; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands., Raboisson P; Janssen Infectious Diseases and Vaccines, Janssen Research & Discovery, Turnhoutseweg 30, Beerse, Belgium., Dhanak D; Discovery Sciences, Janssen Research & Development, Turnhoutseweg 30, Beerse, Belgium.; Discovery Sciences, Janssen Research & Development, 1400 McKean Rd., Spring House, PA, USA., Goudsmit J; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, Leiden, Netherlands.; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Wilson IA; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA. mvandon@its.jnj.com wilson@scripps.edu.; The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, USA.

Publikováno v: Science (New York, N.Y.) [Science] 2019 Mar 08; Vol. 363 (6431).

Contraception by induction of luteinized unruptured follicles with short-acting low molecular weight FSH receptor agonists in female animal models.

Autor: van de Lagemaat R; Merck Research Laboratories, Department of Women's Health, Oss, The Netherlands. lagemaatmail@versatel.nl, van Koppen CJ, Krajnc-Franken MA, Folmer BJ, van Diepen HA, Mulders SM, Timmers CM

Publikováno v: Reproduction (Cambridge, England) [Reproduction] 2011 Dec; Vol. 142 (6), pp. 893-905. Date of Electronic Publication: 2011 Sep 19.

Enhancement of regeneration by Org 2766 after nerve crush depends on the type of neural injury.

Autor: Tonnaer JA; Department of CNS Pharmacology, Organon International B.V., Oss, Netherlands., Schuijers GJ, Van Diepen HA, Peeters BW

Publikováno v: European journal of pharmacology [Eur J Pharmacol] 1992 Apr 07; Vol. 214 (1), pp. 33-7.